Edwin Parsley - Mast Therapeutics Chief Medical Officer & Senior Vice President
President
Dr. Edwin L. Parsley, D.O. is Chief Medical Officer Senior Vice President of Mast Therapeutics, Inc. He served as our interim chief medical officer in September 2014 and has served as chief medical officer of our whollyowned subsidiary, Aires Pharmaceuticals, Inc., since we acquired Aires in February 2014. Prior to the acquisition, he had served as chief medical officer of Aires since April 2011. Dr. Parsley joined Aires from Pfizer where he oversaw clinical trials for Revatio and consulted across molecules in Pfizers pulmonary vascular disease portfolio on clinical trial design, conduct and data interpretation from January 2010 to April 2011. Prior to Pfizer, from January 2009 to September 2009, Dr. Parsley worked at CSL Biotherapies as its pulmonary hypertension medical science specialist and, from 2006 to December 2008, at Encysive Pharmaceuticals, Inc. where he most recently served as its executive director for global medical affairs and drug safety, developing endothelin receptor antagonists for pulmonary hypertension, heart failure, renal failure and resistant hypertension since 2014.
| Age | 53 |
| Tenure | 10 years |
| Professional Marks | Ph.D |
| Phone | 858-552-0866 |
| Web | http://www.masttherapeutics.com |
Mast Therapeutics Management Efficiency
Mast Therapeutics' management efficiency ratios could be used to measure how well Mast Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 14.74 M in liabilities with Debt to Equity (D/E) ratio of 1.08, which is about average as compared to similar companies. Mast Therapeutics has a current ratio of 1.32, which is within standard range for the sector. Debt can assist Mast Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Mast Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Mast Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Mast to invest in growth at high rates of return. When we think about Mast Therapeutics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Jeffrey Greenberg | Skechers USA | 52 | |
| Carey Ford | Precision Drilling | N/A | |
| Niels Espeland | Precision Drilling | N/A | |
| Kyle Andrew | American Eagle Outfitters | 57 | |
| Douglas Evasiuk | Precision Drilling | N/A | |
| Michael Rempell | American Eagle Outfitters | 50 | |
| Douglas Strong | Precision Drilling | N/A | |
| Simon Nankervis | American Eagle Outfitters | 47 | |
| Robert Madore | American Eagle Outfitters | 53 | |
| Gene Stahl | Precision Drilling | 50 | |
| Grant Hunter | Precision Drilling | N/A | |
| Philip Paccione | Skechers USA | 62 | |
| Dennis Parodi | American Eagle Outfitters | 72 | |
| Michael Greenberg | Skechers USA | 61 | |
| Charles Kessler | American Eagle Outfitters | 47 | |
| Veronica Foley | Precision Drilling | N/A | |
| Jennifer Foyle | American Eagle Outfitters | 57 | |
| Luca Zanotti | Tenaris SA ADR | 56 | |
| Darren Ruhr | Precision Drilling | N/A | |
| Darcy Falardeau | Precision Drilling | N/A | |
| Mark Nason | Skechers USA | 62 | |
Management Performance
| Return On Asset | -0.0045 |
Mast Therapeutics Leadership Team
Elected by the shareholders, the Mast Therapeutics' board of directors comprises two types of representatives: Mast Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mast. The board's role is to monitor Mast Therapeutics' management team and ensure that shareholders' interests are well served. Mast Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mast Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gregory Gorgas, Senior Vice President - Commercial | ||
| Peter Greenleaf, Independent Director | ||
| Brian Culley, CEO, Director | ||
| Brandi Roberts, CFO, Senior Vice President Principal Accounting Officer, Principal Financial Officer | ||
| Lewis Shuster, Independent Director | ||
| Howard Dittrich, Independent Director | ||
| Matthew Pauls, Independent Director | ||
| Edwin Parsley, Chief Medical Officer & Senior Vice President | ||
| David Ramsay, Independent Director | ||
| Martin Emanuele, Senior Vice President - Development |
Mast Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Mast Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.0045 | |||
| Profit Margin | (0.29) % | |||
| Operating Margin | (0.17) % | |||
| Current Valuation | 51.07 M | |||
| Shares Outstanding | 254.75 M | |||
| Shares Owned By Insiders | 0.26 % | |||
| Shares Owned By Institutions | 22.90 % | |||
| Number Of Shares Shorted | 7.1 M | |||
| Price To Earning | (0.76) X | |||
| Price To Book | 3.64 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Other Consideration for investing in Mast Stock
If you are still planning to invest in Mast Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Mast Therapeutics' history and understand the potential risks before investing.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |